Yerushalmi, Rinat

Metastatic Behavior of Breast Cancer Subtypes

Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesCancer Cells and Metastasis

Cited by 2,262

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 2,175

Abstract CT071: Talazoparib (TALA) in germline BRCA1/2 (g BRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial

Litton, J. K., Hurvitz, S. A., Mina, L. A., Rugo, H. S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., et al. (2020) · Cancer Research

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 10